Abstract
We examined 46 non-small-cell lung carcinomas (NSCLCs) for the presence of p53 mutations in exons 4-9, positive p53 immunostaining and loss of heterozygosity (LOH) in the TP53 locus. p53 mutations were detected in 13 tumour samples (28.3%), whereas overexpression of the p53 protein was found in 30 of 45 (67%) samples. Allelic loss was found in 9 of 38 (23.6%) informative cases. The statistical analysis revealed no significant correlation between p53 mutations and clinicopathological data, although mutations appear to occur more frequently in squamous cell carcinomas (7 of 18) than in adenocarcinomas (2 of 15). All but three individuals in this study group smoked. In contrast to previous reports, we found a higher prevalence of GC-->AT transitions than of GC-->TA transversions, as expected in a smoking population. A trend was found between p53-positive immunostaining and a history of heavy smoking (76-126 pack-years) and was inversely correlated with allelic deletion (LOH) at the TP53 locus. Eight of the 12 NSCLCs containing p53 mutations also had concomitant p53 overexpression, and it is of specific note that three of the four tumours containing p53 'mutations' with no overexpression of the p53 protein had either insertions or deletions in the p53 gene. No correlation was found between p53 mutations and fractional allele loss or ras mutations. p53 mutations in this Merseyside population in the UK do not appear to be as common as in other reports for NSCLC and exhibit predominance of GC-->AT transitions preferentially at non-CpG sites, suggesting that other carcinogens in addition to those in tobacco smoke may be involved in NSCLC in the Merseyside area of the UK.
Full text
PDF





Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Carbone D. P., Mitsudomi T., Chiba I., Piantadosi S., Rusch V., Nowak J. A., McIntire D., Slamon D., Gazdar A., Minna J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest. 1994 Dec;106(6 Suppl):377S–381S. [PubMed] [Google Scholar]
- Chiba I., Takahashi T., Nau M. M., D'Amico D., Curiel D. T., Mitsudomi T., Buchhagen D. L., Carbone D., Piantadosi S., Koga H. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. Oncogene. 1990 Oct;5(10):1603–1610. [PubMed] [Google Scholar]
- DeMarini D. M. Genotoxicity of tobacco smoke and tobacco smoke condensate. Mutat Res. 1983 Jan;114(1):59–89. doi: 10.1016/0165-1110(83)90019-2. [DOI] [PubMed] [Google Scholar]
- DeMarini D. M., Shelton M. L., Levine J. G. Mutation spectrum of cigarette smoke condensate in Salmonella: comparison to mutations in smoking-associated tumors. Carcinogenesis. 1995 Oct;16(10):2535–2542. doi: 10.1093/carcin/16.10.2535. [DOI] [PubMed] [Google Scholar]
- Field J. K., Kiaris H., Risk J. M., Tsiriyotis C., Adamson R., Zoumpourlis V., Rowley H., Taylor K., Whittaker J., Howard P. Allelotype of squamous cell carcinoma of the head and neck: fractional allele loss correlates with survival. Br J Cancer. 1995 Nov;72(5):1180–1188. doi: 10.1038/bjc.1995.483. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Field J. K., Neville E. M., Stewart M. P., Swift A., Liloglou T., Risk J. M., Ross H., Gosney J. R., Donnelly R. J. Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer. Br J Cancer. 1996 Dec;74(12):1968–1974. doi: 10.1038/bjc.1996.661. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
- Hollstein M., Rice K., Greenblatt M. S., Soussi T., Fuchs R., Sørlie T., Hovig E., Smith-Sørensen B., Montesano R., Harris C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994 Sep;22(17):3551–3555. [PMC free article] [PubMed] [Google Scholar]
- Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 1991 Jul 5;253(5015):49–53. doi: 10.1126/science.1905840. [DOI] [PubMed] [Google Scholar]
- Husgafvel-Pursiainen K., Ridanpä M., Anttila S., Vainio H. p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J Occup Environ Med. 1995 Jan;37(1):69–76. doi: 10.1097/00043764-199501000-00010. [DOI] [PubMed] [Google Scholar]
- Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
- Lee L. N., Shew J. Y., Sheu J. C., Lee Y. C., Lee W. C., Fang M. T., Chang H. F., Yu C. J., Yang P. C., Luh K. T. Exon 8 mutation of p53 gene associated with nodal metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1667–1671. doi: 10.1164/ajrccm.150.6.7952630. [DOI] [PubMed] [Google Scholar]
- Lehman T. A., Bennett W. P., Metcalf R. A., Welsh J. A., Ecker J., Modali R. V., Ullrich S., Romano J. W., Appella E., Testa J. R. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res. 1991 Aug 1;51(15):4090–4096. [PubMed] [Google Scholar]
- Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
- Lohmann D., Pütz B., Reich U., Böhm J., Präuer H., Höfler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol. 1993 Mar;142(3):907–915. [PMC free article] [PubMed] [Google Scholar]
- Mitsudomi T., Oyama T., Kusano T., Osaki T., Nakanishi R., Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst. 1993 Dec 15;85(24):2018–2023. doi: 10.1093/jnci/85.24.2018. [DOI] [PubMed] [Google Scholar]
- Mitsudomi T., Steinberg S. M., Nau M. M., Carbone D., D'Amico D., Bodner S., Oie H. K., Linnoila R. I., Mulshine J. L., Minna J. D. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992 Jan;7(1):171–180. [PubMed] [Google Scholar]
- Neville E. M., Stewart M., Myskow M., Donnelly R. J., Field J. K. Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene. 1995 Aug 3;11(3):581–585. [PubMed] [Google Scholar]
- Rämet M., Castrén K., Järvinen K., Pekkala K., Turpeenniemi-Hujanen T., Soini Y., Päkkö P., Vähäkangas K. p53 protein expression is correlated with benzo[a]pyrene-DNA adducts in carcinoma cell lines. Carcinogenesis. 1995 Sep;16(9):2117–2124. doi: 10.1093/carcin/16.9.2117. [DOI] [PubMed] [Google Scholar]
- Sameshima Y., Matsuno Y., Hirohashi S., Shimosato Y., Mizoguchi H., Sugimura T., Terada M., Yokota J. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene. 1992 Mar;7(3):451–457. [PubMed] [Google Scholar]
- Shopland D. R., Eyre H. J., Pechacek T. F. Smoking-attributable cancer mortality in 1991: is lung cancer now the leading cause of death among smokers in the United States? J Natl Cancer Inst. 1991 Aug 21;83(16):1142–1148. doi: 10.1093/jnci/83.16.1142. [DOI] [PubMed] [Google Scholar]
- Sidransky D., Hollstein M. Clinical implications of the p53 gene. Annu Rev Med. 1996;47:285–301. doi: 10.1146/annurev.med.47.1.285. [DOI] [PubMed] [Google Scholar]
- Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y., Takahashi T., Ueda R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 1992 Feb 1;52(3):734–736. [PubMed] [Google Scholar]
- Takeshima Y., Seyama T., Bennett W. P., Akiyama M., Tokuoka S., Inai K., Mabuchi K., Land C. E., Harris C. C. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet. 1993 Dec 18;342(8886-8887):1520–1521. doi: 10.1016/s0140-6736(05)80087-x. [DOI] [PubMed] [Google Scholar]
- Tasheva E. S., Roufa D. J. Densely methylated DNA islands in mammalian chromosomal replication origins. Mol Cell Biol. 1994 Sep;14(9):5636–5644. doi: 10.1128/mcb.14.9.5636-5644.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Westra W. H., Offerhaus G. J., Goodman S. N., Slebos R. J., Polak M., Baas I. O., Rodenhuis S., Hruban R. H. Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am J Surg Pathol. 1993 Mar;17(3):213–220. doi: 10.1097/00000478-199303000-00001. [DOI] [PubMed] [Google Scholar]
- Yang A. S., Gonzalgo M. L., Zingg J. M., Millar R. P., Buckley J. D., Jones P. A. The rate of CpG mutation in Alu repetitive elements within the p53 tumor suppressor gene in the primate germline. J Mol Biol. 1996 May 3;258(2):240–250. doi: 10.1006/jmbi.1996.0246. [DOI] [PubMed] [Google Scholar]
- Yin Y., Tainsky M. A., Bischoff F. Z., Strong L. C., Wahl G. M. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 1992 Sep 18;70(6):937–948. doi: 10.1016/0092-8674(92)90244-7. [DOI] [PubMed] [Google Scholar]
- Zheng J., Shu Q., Li Z. H., Tsao J. I., Weiss L. M., Shibata D. Patterns of p53 mutations in squamous cell carcinoma of the lung. Acquisition at a relatively early age. Am J Pathol. 1994 Dec;145(6):1444–1449. [PMC free article] [PubMed] [Google Scholar]



